Search Results for: Bill Fox

Pfizer has been forced to rein in its profit expectations for 2005 after increased competition to its flagship cholesterol-lowering drug, Lipitor (atorvastatin), added to the burden of coping with the pressures facing its COX-2 inhibitor franchise.

A lawsuit filed yesterday against Pfizer is claiming that the world’s largest drugmaker inappropriately marketed its cholesterol-lowering drug Lipitor (atorvastatin) to patients who have not been proved to benefit from the product.

Shares in Germany’s Schering AG dropped almost 4% on the New York Stock Exchange yesterday after the firm unveiled full data from a late-stage study of its oral anti-angiogenesis agent, PTK/ZK, showing the compound had failed to stop disease progression in first-line colorectal cancer patients. However, the sliding share price may have come as somewhat of a surprise to the firm, which first discussed the findings back in March, along with partner Novartis [[21/03/05a]].